Ken Frazier is joining
General Catalystas its chairman of health assurance initiatives, a role the venture capital firm created to ramp up its investments in healthcare and pharma.
Frazier just recently stepped down from his previous role as CEO of Merck, where he spent nearly a decade encouraging the pharma giant to prioritize research and pursue novel vaccines and therapeutics.
At General Catalyst, he’ll be laying out strategy for the firm’s healthcare initiatives, fostering partnerships between healthcare and pharma and targeting health equity opportunities. He’ll also be in control of its $600 million Health Assurance Fund which was unveiled back in April.
Teva rejigs top management
globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
Big step forward for £15m homes plan at Middleton St George | Darlington and Stockton Times
darlingtonandstocktontimes.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from darlingtonandstocktontimes.co.uk Daily Mail and Mail on Sunday newspapers.
Big step forward for £15m homes plan at Middleton St George
thenorthernecho.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenorthernecho.co.uk Daily Mail and Mail on Sunday newspapers.
Operator
Good day, and thank you for standing by, and welcome to the Teva Pharmaceutical first-quarter 2021 financial results conference call. [Operator instructions] Please be advised that today s conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Kevin Mannix, senior vice president, head of investor relations. Please go ahead, sir.
Kevin Mannix
Senior Vice President, Head of Investor Relations
Thank you, Anette. And thank you, everyone, for joining us today to discuss Teva s first-quarter 2021 financial results. We hope you ve had an opportunity to review our press release, which was issued about an hour ago. A copy of the release, as well as a copy of the slides being presented on this call can be found on our website at www.tevapharm.com.